Navigation Links
Celsion Receives COMP Recommendation for Orphan Drug Designation in Europe for ThermoDox® to Treat Primary Liver Cancer
Date:11/11/2010

COLUMBIA, Md., Nov. 11, 2010 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN), a leading oncology drug development company, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on the application for Orphan Drug Designation for ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, for the treatment of hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer.  A positive opinion by the COMP immediately precedes official designation of ThermoDox® as an orphan drug by the EMA.  ThermoDox® is currently being evaluated under a Special Protocol Assessment with the FDA in a 600 patient pivotal Phase III trial (the HEAT study) in patients with non-resectable primary liver cancer at 76 clinical sites in 11 different countries.  ThermoDox® has previously received Orphan Drug designation by the U.S. Food and Drug Administration (FDA).  In addition, the HEAT study has been designated as a Fast Track Development Program by the FDA.

Orphan designation for a medicinal product by the EMA provides for scientific advice and regulatory assistance from the EMA during the product development phase, direct access to centralized marketing authorization, and certain financial incentives.  The designation also provides 10 years of marketing exclusivity subsequent to product approval.  Orphan drugs are eligible for full reduction of fees associated with pre-authorization inspections, as well as full reduction of marketing application fees and annual fees for qualifying companies.

"We are very pleased to receive a positive opinion from the Committee for Orphan Medicinal Products, which immediately precedes final Orphan Drug designation from the EMA, for ThermoDox®," stated Mr. Michael H. Tardugno,
'/>"/>

SOURCE Celsion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Celsion Announces ThermoDoxs Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium
2. Data Monitoring Committee Unanimously Recommends Continuation of Celsions Phase III ThermoDox® HEAT Study to Treat Primary Liver Cancer
3. Celsion Receives SBIR Grant To Expand Its Technology Platform
4. Celsion Receives Fast Track Designation for ThermoDox® Development Program to Treat Primary Liver Cancer
5. Celsion Announces CFO Departure
6. Stereotaxis Receives Commitment to Increase and Extend Credit Facility
7. Prolia™ (denosumab) Receives Best New Drug Honor at Scrip Awards
8. CMUs Bone Tissue Engineering Center Receives Defense Department Research Grant to Help Injured Soldiers
9. AccuVein Receives Grant for its Award Winning AV300 Vein Illumination System
10. Cocrystal Discovery Receives Awards for Its Novel Antiviral Drug Development Programs
11. DNA Medicine Institute Receives Qualifying Therapeutic Discovery Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 The clinical and ... be the difference between a product,s success or failure. ... and stratify KOL targets – and then to coordinate ... of strong relationships upon which successful KOL engagement rests. ... companies have identified internal inconsistencies in their KOL management ...
(Date:8/29/2014)... The Competitive Intelligence (CI) function is evolving ... leaders who adjust will succeed, and those who don,t ... Practices, LLC study CI leaders from 32 biopharmaceutical organizations ... - Use secondary research whenever possible - it,s effective, ... Internal staff who are creative thinkers provide the CI ...
(Date:8/29/2014)... Aug. 29, 2014 /PRNewswire-iReach/ -- SAM Medical Products ... for the SAM Junctional Tourniquet.  ... SAM Medical Products announced today that it has ... address a potential issue with a clip used ... Axilla application of the SAM Junctional Tourniquet (SJT).  ...
Breaking Medicine Technology:Implementing a Strategic Thought Leader Management & Engagement System 2Using the Competitive Intelligence Function to Drive Better Business Decisions in the Pharmaceutical Sector 2SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
(Date:8/29/2014)... Healthpointe Medical Group, one of ... center from LAXMed. The medical center is less than 2 ... west of the 405 freeway. , The LAX clinic ... LAX center is located at: 8610 S. Sepulveda Blvd., Suite ... Healthpointe LAX office will provide the same comprehensive services ...
(Date:8/29/2014)... The family of a California woman ... dialysis treatments has filed a GranuFlo lawsuit ( http://www.thegranuflolawsuit.com ... of Fresenius Medical Care’s GranuFlo and NaturaLyte dialysis concentrates, ... file d in Alameda County Superior Court on July ... resulted in metabolic alkalosis, a dangerous elevation of ...
(Date:8/29/2014)... 29, 2014 Today, NBC’s “The ... who profiled a handful of safe, back to ... Research. This year, many schools will include earphones ... innovator of hearing wellness solutions, offers the best ... Earphones, offered in yellow, pink and black, sound ...
(Date:8/29/2014)... Reinberg HealthDay Reporter ... majority of American babies are getting the vaccines they ... officials said Thursday. More than 90 percent of ... and rubella (MMR); polio; hepatitis B and chickenpox (varicella), ... Prevention. "Nationally, vaccination among children 19 to 35 ...
(Date:8/29/2014)... Food and Drug Administration (FDA)-approved treatment for decreasing ... effective at reducing fracture risk as other current ... loss. With the use of wide- and small-angle ... out experiments at the U.S. Department of Energy,s ... Laboratory that revealed an additional mechanism underlying raloxifene ...
Breaking Medicine News(10 mins):Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 4Health News:The Today Show Features ETY•Kids® Safe-Listening Earphones by Etymotic 2Health News:Most U.S. Babies Get Their Vaccines: CDC 2Health News:Most U.S. Babies Get Their Vaccines: CDC 3Health News:Revealing a novel mode of action for an osteoporosis drug 2
... with a drug that targets two genes that ... this deadly disease, according to cancer researchers. The ... safer and more effective way of targeting cancer-causing ... , "It is a very selective and ...
... message boards, videos and advice , , MONDAY, Sept. 15 ... cancer patients learn more about how they can preserve ... Northwestern University in Chicago. , "It,s overwhelming for ... fertility preservation at the same time that they are ...
... Sept. 15 Yearbook photos capture school,portraits for years ... a,yearbook photo that they would prefer to erase -- ... yearbook photos this year, and to,kick-off the launch of ... & CLEAR(R) is inviting teens to,"Erase Their Worst Year ...
... Consumer coalition calls for quality standards to protect Pennsylvania ... families from inadequate regulations, ... allow facilities to rent rooms to residents that,do not meet ... wheelchairs or walkers., While new assisted living construction would ...
... LSU Health Sciences Center New Orleans School of ... the Robert Wood Johnson Foundation (RWJF) to provide ... disadvantaged backgrounds in an accelerated nursing degree program. ... Career Alternative RN Education, or CARE, Program, expanding ...
... HILL Nearly every child who receives an antipsychotic ... atypical drugs, such as olanzapine and risperidone. However, there ... effective than the older, first-generation medications., ,Now a study ... School of Medicine suggests that molindone, a first-generation drug, ...
Cached Medicine News:Health News:Nanomedical approach targets multiple cancer genes, shrinks tumors more effectively 2Health News:Nanomedical approach targets multiple cancer genes, shrinks tumors more effectively 3Health News:Web Site Helps Cancer Patients With Fertility Preservation 2Health News:CLEAN & CLEAR(R) Is Inviting Teens to 'Erase Their Worst Yearbook Picture' With The NEW CLEAN & CLEAR(R) Advantage(R) Blackhead Eraser(TM) Exfoliating Cleanser 2Health News:Proposed Assisted Living Regulations Would Allow Facilities to Rent Inaccessible Rooms to Persons Who Use Wheelchairs or Walkers 2Health News:Proposed Assisted Living Regulations Would Allow Facilities to Rent Inaccessible Rooms to Persons Who Use Wheelchairs or Walkers 3Health News:LSUHSC awarded grant to address nursing shortage 2Health News:First generation antipsychotic drugs as effective as newer ones in some children 2Health News:First generation antipsychotic drugs as effective as newer ones in some children 3
... The Integrity ADx pacemaker ... world's smallest dual-chamber pacemaker, ... pacemaker technology, including the ... the first U.S. commercially ...
... The Affinity pacemaker ... today's smallest, truly automatic ... effective combination of advanced ... Affinity DR pacemaker incorporates ...
Innovative new tools for more efficient patient management begin when the pacemaker is implanted. These sophisticated tools are in effect each day, and they help automate follow-up tasks....
... The first-ever completely automatic ... that make it sophisticated yet ... a wide range of diagnostic ... without clinician intervention. This allows ...
Medicine Products: